Partnerships

1. Public: Jordan Food and Drug Administration (JFDA). https://jfda.jo/Default/Ar

The Medication Safety Research Group (SAFE-MED) at the University of Jordan is uniquely positioned to establish a fruitful partnership with the Jordan Food and Drug Administration (JFDA) by aligning academic research with national regulatory priorities. SAFE-MED’s expertise in pharmacovigilance, pharmacoepidemiology, pharmacogenetics, and clinical pharmacy complements the JFDA’s mandate to ensure the safety, efficacy, and quality of medicines available in Jordan. Through collaborative projects, the group can provide evidence on adverse drug reactions, drug–drug interactions, and inappropriate prescribing in vulnerable populations that can directly inform regulatory decision-making and policy. Joint initiatives could also focus on developing national databases for medication-related harms, implementing clinical pharmacist-led interventions to improve rational drug use, and piloting AI-based pharmacovigilance and decision-support systems. Such a partnership would not only strengthen medication safety infrastructure in Jordan but also position the country as a regional leader in regulatory science and patient safety.

2. Public: JPA (Jordanian Pharmacist Association's) Pharmacy Pioneering Initiative. https://jpa.org.jo/.

Collaboration with the JPA is via conducting lectures, presentations, consultations, participating in conferences, surveys, awareness campaigns and curriculum empowering. PharmD Batool AlKhawaldeh is the initiator of the Pharmacy Pionering Initiative (PPI) at the Jordan Pharmacisst Association and organized the PPI opening event with the participation of prominent pharmacists including decision makers.

How does this collaboration contribute to achieving the goals of the research group:

Ensures that the group's work is not only academic but also embedded into Jordan’s pharmacy practice and policy, particularly benefiting the elderly and polypharmacy patients.

3. Private: Jordanian Pharmaceutical Manufacturing Co. (JPM). http://www.jpm.com.jo/

Collaboration with JPM generated a publication by Prof. Kasabri & Dr. Suyagh that was also presented at a local conference. The publication is entitled "‘‘Prevalence of Cardiovascular Diseases Risk Factors Among Jordanians’’ was published in JOURNAL OF THE SAUDI HEART ASSOCIATION in 2020. It was also presented at ‘’The Role Of Social Media In Supporting Healthcare Services’’ during The First International Health Conference For The Jordan Healing and Health Bank (online), 8-12/12/2020; Ministry Of Health And University Of Jordan.

4. International: FIP (International Pharmaceutical Federation). Link: https://www.fip.org/.

Dr. Maysa Suyagh and PharmD Batool AlKhawaldeh are the FIP members and participate regularly in the annual FIP conferences. PharmD Batool AlKhawaldeh appointed as a Global Lead for Continuing Professional Development Strategies within the International Pharmaceutical Federation (FIP) Hub for the 2025-2027 term.

How does this collaboration contribute to achieving the goals of the research group:

Anchors our research group in the global pharmacy research ecosystem, ensuring Jordan’s context is represented while benefiting from international advances.

The Role of Partnerships in Advancing Medication Safety Research

By working with both national stakeholders and international leaders, the group not only strengthens its scientific foundations but also ensures that research is translated into practice, policy, and innovation.

1. Fostering Innovation

Collaborations with professional bodies such as the Jordan Pharmacists Association (JPA) and global organizations like the International Pharmaceutical Federation (FIP) open avenues for new research methodologies, advanced technologies, and cross-disciplinary approaches.

By combining local insights with global expertise, the group can explore emerging fields such as pharmacogenetics and selective cytotoxicity of novel therapeutics, ensuring Jordanian research remains at the cutting edge.

2. Expanding Scope of Research

National partnerships (e.g., JPA) ensure the research agenda addresses real-world problems such as polypharmacy, adverse effects, and safe prescribing in vulnerable populations.

International collaborations (e.g., FIP) broaden the scope to global health challenges, enabling comparative studies and shared solutions in pharmacovigilance, rational medicine use, and medication safety systems.

3. Amplifying Impact

Through JPA, findings are integrated into pharmacy practice and education in Jordan, directly benefiting patients, practitioners, and policy makers.

Through FIP, research outcomes reach a global audience, positioning Jordan as a contributor to international medication safety strategies.

Partnerships ensure that research outputs influence not only academic literature, but also clinical practice, regulatory policy, and patient safety initiatives.

🌍 Strategic Value

These partnerships transform the group from a research cluster into a hub of innovation and influence. They:

Bridge the gap between science and practice.

Create platforms for knowledge exchange and mutual learning.

Strengthen Jordan’s visibility within the global pharmaceutical research community.

Secure the sustainability of the group’s mission by embedding it in national priorities and international networks.

Trending

الجامعة الأردنيّة تطلق مجموعة بحثيّة متخصّصة بعنوان "سلامة الدواء (SAFE-MED)"

Partnerships